PHARMAFILE.COM: Keyword Density Checker

Total words: 3659 | 2-word phrases: 934 | 3-word phrases: 1091 | 4-word phrases: 1168

PAGE INFO

Title	Try to keep the title under 60 characters (85 characters) Pharmafile - Pharmaceutical industry news and insight from Pharmafocus and Pharmafile
Description	Try to keep the meta description between 50 - 160 characters (205 characters) Pharmafile.com is a leading portal for the pharmaceutical industry, providing pharma news, analysis, events, and pharma service company listings in association with Pharmafocus and Pharmafile publications.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (115 characters) OSE Immunotherapeutics and Boehringer Ingelheim collaborate on cancer and cardio-renal-metabolic disease treatments

#	Keyword	Frequency	Density
1	research and development	6	0.55%
2	announced that the	6	0.55%
3	2024 research and	6	0.55%
4	announced that it	5	0.46%
5	may 22 2024	5	0.46%
6	that it has	4	0.37%
7	has announced that	4	0.37%
8	have announced that	4	0.37%
9	the technical storage	4	0.37%
10	acquire mirus bio	3	0.27%
11	may 24 2024	3	0.27%
12	the urgent need	3	0.27%
13	and boehringer ingelheim	3	0.27%
14	2024 business services	3	0.27%
15	entered into a	3	0.27%
16	immunotherapeutics and boehringer	3	0.27%
17	technical storage or	3	0.27%
18	bio for 600m	3	0.27%
19	mirus bio for	3	0.27%
20	announced that they	3	0.27%
21	results from phase	3	0.27%
22	from phase 3	3	0.27%
23	human immunology biosciences	3	0.27%
24	to acquire mirus	3	0.27%
25	and development astrazeneca	3	0.27%
26	phase 3 trial	3	0.27%
27	biogen to acquire	3	0.27%
28	to acquire human	2	0.18%
29	immunology biosciences for	2	0.18%
30	biosciences for 115bn	2	0.18%

#	Keyword	Frequency	Density
1	have announced that the	4	0.34%
2	the technical storage or	3	0.26%
3	immunotherapeutics and boehringer ingelheim	3	0.26%
4	2024 research and development	3	0.26%
5	announced that it has	3	0.26%
6	mirus bio for 600m	3	0.26%
7	acquire mirus bio for	3	0.26%
8	to acquire mirus bio	3	0.26%
9	research and development astrazeneca	3	0.26%
10	results from phase 3	3	0.26%
11	have announced that they	3	0.26%
12	from its phase 3	2	0.17%
13	treatments may 24 2024	2	0.17%
14	trials the urgent need	2	0.17%
15	the urgent need for	2	0.17%
16	urgent need for patients	2	0.17%
17	need for patients to	2	0.17%
18	immunology biosciences for 115bn	2	0.17%
19	24 2024 research and	2	0.17%
20	may 24 2024 research	2	0.17%
21	disease treatments may 24	2	0.17%
22	that is used exclusively	2	0.17%
23	cardiorenalmetabolic disease treatments may	2	0.17%
24	for patients to be	2	0.17%
25	patients to be heard	2	0.17%
26	ingelheim collaborate on cancer	2	0.17%
27	boehringer ingelheim collaborate on	2	0.17%
28	and boehringer ingelheim collaborate	2	0.17%
29	biosciences for 115bn may	2	0.17%
30	is used exclusively for	2	0.17%
31	access that is used	2	0.17%
32	for the legitimate purpose	2	0.17%
33	to acquire human immunology	2	0.17%
34	the legitimate purpose of	2	0.17%
35	announced that they have	2	0.17%
36	requested by the subscriber	2	0.17%
37	by the subscriber or	2	0.17%
38	the subscriber or user	2	0.17%
39	merck to acquire mirus	2	0.17%
40	biogen to acquire human	2	0.17%

#	URL	Whois	Check
1	https://www.pharmafocus.com/	Whois	pharmafocus.com
2	https://www.pharmafocus.com/collections	Whois	pharmafocus.com
3	https://www.pharmafocus.com/articles	Whois	pharmafocus.com
4	https://www.pharmafocus.com/	Whois	pharmafocus.com
5	https://twitter.com/Pharmafocus	Whois	twitter.com
6	http://www.pmgrouplive.com	Whois	pmgrouplive.com
7	https://cookiedatabase.org/tcf/purposes/	Whois	cookiedatabase.org